Abstract
The public health and economic burden of heart failure (HF) is staggering and the need for relevant pathophysiologic and clinical biomarkers to advance the field and improve HF therapy remains high. Renal dysfunction is common among HF patients and is associated with increased HF hospitalization and mortality. It is widely recognized that mechanisms contributing to HF pathogenesis include a complex bidirectional interaction between the kidney and heart, encompassed by the term cardiorenal syndrome (CRS). Among a new wave of urinary biomarkers germane to CRS, C-type natriuretic peptide (CNP) has emerged as an innovative biomarker of renal structural and functional impairment in HF and chronic renal disease states. CNP is a hormone, synthesized in the kidney, and is an important regulator of cell proliferation and organ fibrosis. Hypoxia, cytokines and fibrotic growth factors, which are inherent to both cardiac and renal remodeling processes, are among the recognized stimuli for CNP production and release. In this review we aim to highlight current knowledge regarding the biology and pathophysiological correlates of urinary CNP, and its potential clinical utility as a diagnostic and prognostic biomarker in HF and renal disease states.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 108-113 |
| Number of pages | 6 |
| Journal | Clinica Chimica Acta |
| Volume | 443 |
| DOIs | |
| State | Published - Mar 1 2015 |
Fingerprint
Keywords
- Biomarker
- C-type natriuretic peptide
- Cardiorenal syndrome
- Heart failure
- Renal remodeling
ASJC Scopus subject areas
- Biochemistry
- Clinical Biochemistry
- Biochemistry, medical
Cite this
Urinary C-type natriuretic peptide : An emerging biomarker for heart failure and renal remodeling. / Zakeri, Rosita; Burnett, John C Jr.; Sangaralingham, S Jeson.
In: Clinica Chimica Acta, Vol. 443, 01.03.2015, p. 108-113.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Urinary C-type natriuretic peptide
T2 - An emerging biomarker for heart failure and renal remodeling
AU - Zakeri, Rosita
AU - Burnett, John C Jr.
AU - Sangaralingham, S Jeson
PY - 2015/3/1
Y1 - 2015/3/1
N2 - The public health and economic burden of heart failure (HF) is staggering and the need for relevant pathophysiologic and clinical biomarkers to advance the field and improve HF therapy remains high. Renal dysfunction is common among HF patients and is associated with increased HF hospitalization and mortality. It is widely recognized that mechanisms contributing to HF pathogenesis include a complex bidirectional interaction between the kidney and heart, encompassed by the term cardiorenal syndrome (CRS). Among a new wave of urinary biomarkers germane to CRS, C-type natriuretic peptide (CNP) has emerged as an innovative biomarker of renal structural and functional impairment in HF and chronic renal disease states. CNP is a hormone, synthesized in the kidney, and is an important regulator of cell proliferation and organ fibrosis. Hypoxia, cytokines and fibrotic growth factors, which are inherent to both cardiac and renal remodeling processes, are among the recognized stimuli for CNP production and release. In this review we aim to highlight current knowledge regarding the biology and pathophysiological correlates of urinary CNP, and its potential clinical utility as a diagnostic and prognostic biomarker in HF and renal disease states.
AB - The public health and economic burden of heart failure (HF) is staggering and the need for relevant pathophysiologic and clinical biomarkers to advance the field and improve HF therapy remains high. Renal dysfunction is common among HF patients and is associated with increased HF hospitalization and mortality. It is widely recognized that mechanisms contributing to HF pathogenesis include a complex bidirectional interaction between the kidney and heart, encompassed by the term cardiorenal syndrome (CRS). Among a new wave of urinary biomarkers germane to CRS, C-type natriuretic peptide (CNP) has emerged as an innovative biomarker of renal structural and functional impairment in HF and chronic renal disease states. CNP is a hormone, synthesized in the kidney, and is an important regulator of cell proliferation and organ fibrosis. Hypoxia, cytokines and fibrotic growth factors, which are inherent to both cardiac and renal remodeling processes, are among the recognized stimuli for CNP production and release. In this review we aim to highlight current knowledge regarding the biology and pathophysiological correlates of urinary CNP, and its potential clinical utility as a diagnostic and prognostic biomarker in HF and renal disease states.
KW - Biomarker
KW - C-type natriuretic peptide
KW - Cardiorenal syndrome
KW - Heart failure
KW - Renal remodeling
UR - http://www.scopus.com/inward/record.url?scp=84924260095&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84924260095&partnerID=8YFLogxK
U2 - 10.1016/j.cca.2014.12.009
DO - 10.1016/j.cca.2014.12.009
M3 - Article
C2 - 25512164
AN - SCOPUS:84924260095
VL - 443
SP - 108
EP - 113
JO - Clinica Chimica Acta
JF - Clinica Chimica Acta
SN - 0009-8981
ER -